To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: Claritin Is Logical Alternative to Seldane, Reports Schering-Plough URL: http://www.pslgroup.com/dg/123A2.htm Doctor's Guide January 14, 1997
MADISON, N.J., Jan. 14, 1997 -- Schering-Plough Corporation (NYSE: SGP) today issued the following statement in response to recent news reports that the U.S. Food and Drug Administration (FDA) is recommending removal from the market of Seldane (terfenadine) and Seldane-D as well as generic versions of the drug because of on-going cardiovascular safety concerns. The FDA also is recommending that patients taking Seldane consult their physicians for alternative treatment options. In seeking treatment options, Schering-Plough strongly believes that physicians and allergy sufferers should consider CLARITIN(R) (loratadine), the leading nonsedating prescription antihistamine in the United States and the world, for the following reasons: -- CLARITIN has a proven history of safety and efficacy that includes more than 3 billion patient days of use. -- For seasonal allergic rhinitis sufferers, CLARITIN provides rapid-acting relief that lasts for a full 24 hours. -- CLARITIN is the only once-a-day nonsedating antihistamine sold in the United States that does not carry a black box warning. -- The CLARITIN product line offers more treatment options than any other prescription antihistamine available. -- The CLARITIN line includes: CLARITIN(R), a once-daily nonsedating antihistamine; CLARITIN(R)-D 24 Hour; a once-daily version with a decongestant -- the first and only prescription medication that provides 24 hours of complete symptom coverage in a single tablet; CLARITIN(R)-D 12 Hour, a twice-daily version with a decongestant; and CLARITIN(R) Syrup, the first and only nonsedating antihistamine for children age 6 and above. In December 1996, U.S. marketing clearance was received for CLARITIN(R) RediTabs(TM), the first and only nondrowsy allergy product in a ready-to-take, rapidly disintegrating tablet. -- The CLARITIN brand is reimbursed by more than 93 percent of managed care plans. Schering-Plough is a research-based company engaged in the discovery, development, manufacturing and marketing of pharmaceutical and health care products worldwide. --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.